Wednesday, 22 January 2025
  
Login

Australia's most trusted
source of pharma news

Wednesday, 22 January 2025
News

2025 PBS listings off and racing

Posted 17 January 2025 PM

A good start to the year for four companies which kicked off 2025 by notching either a new or expanded PBS listing and our readers wanted to know who'd made the cut, making it our top story this week.

Pfizer's PARP inhibitor Talzenna crossed the finish line alongside AstraZeneca's cancer drug Lynparza, which won an expansion. The Federal Government also announced subsidy for Servier's Risvan for schizophrenia and Sandoz' Hyrimoz - a citrate-free, high concentration biosimilar of AbbVie's Humira. Get the details in: Four PBS listings kick off 2025 

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (5)

Sales & Customer Relations (14)

Clinical & Medical, R&D (5)

Regulatory, Pharmacovigilance & QA (2)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.